Heather Rae Sanders

US Patent:

8546552, Oct 1, 2013

Filed:

Dec 22, 2010

Appl. No.:

12/975908

Inventors:

Heather R. Sanders - Winchester CA, US
Maher Albitar - Cote De Caza CA, US

Assignee:

Quest Diagnostics Investments Incorporated - Wilmington DE

International Classification:

C07H 21/04
C12Q 1/68
C12P 19/34

US Classification:

536 2433, 435 61, 435 611, 435 612

Abstract:

Described herein are methods, compositions and kits directed to the detection the 5′ portion of TMPRSS2 mRNA for the detection and diagnosis of prostate disease including prostate cancer and benign prostatic hyperplasia.

US Patent:

20090181378, Jul 16, 2009

Filed:

Feb 21, 2008

Appl. No.:

12/035356

Inventors:

Heather R. Sanders - Winchester CA, US
Kevin Z. Qu - Irvine CA, US
Charles M. Strom - San Clemente CA, US
Richard A. Bender - Dana Point CA, US

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

Provided herein are methods and compositions for detection of a nucleic acid target in a sample. The methods and compositions use primer directed amplification in conjunction with nucleic acid fragmentation. The methods have high sensitivity even in the presence of a large amount of non-target nucleic acid. Also provided are oligonucleotides and kits useful in the method. Exemplary nucleic acid targets are those with mutant gene sequence such as mutant sequence of the EGFR, APC, TMPRSS2, ERG and ETV1 genes.

US Patent:

20100304390, Dec 2, 2010

Filed:

May 24, 2010

Appl. No.:

12/786266

Inventors:

Heather R. Sanders - Winchester CA, US
Maher Albitar - Coto De Caza CA, US
Aurelia Meloni-Ehrig - Gainesville VA, US

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

Described herein are methods, compositions and kits directed to the detection of gene dysregulations such as those arising from gene fusions and/or chromosomal abnormalities, e.g. translocations, insertions, inversions and deletions. Samples containing dysregulated gene(s) of interest may show independent expression patterns for the 5′ and 3′ regions of the gene. The methods, compositions and kits are useful for detecting mutations that cause the differential expression of a 5′ portion of a target gene relative to the 3′ region of the target gene.

US Patent:

20110159550, Jun 30, 2011

Filed:

Dec 20, 2010

Appl. No.:

12/973747

Inventors:

Heather Sanders - Winchester CA, US

International Classification:

C12P 19/34

US Classification:

435 912

Abstract:

The invention provides methods for isolating RNA from the soluble fraction of urine. The methods can be used for detecting the presence or absence of an RNA, or quantifying the amount of an RNA. The methods are useful for diagnosing an individual suspected of having a disease by detecting the level of RNA associated with the disease in the soluble fraction of urine. The methods are also useful for prognosing an individual diagnosed with a disease by detecting the level of RNA associated with the disease in the soluble fraction of urine.

US Patent:

20130330719, Dec 12, 2013

Filed:

Dec 16, 2010

Appl. No.:

13/518232

Inventors:

Heather R. Sanders - Winchester CA, US
Maher Albitar - Coto De Caza CA, US
Aurelia Meloni-Ehrig - Gainesville VA, US

International Classification:

C12Q 1/68
C12Q 1/48
C07K 16/40

US Classification:

435 611, 536 232, 5303892, 435 612, 536 2433, 435 71

Abstract:

The present disclosure relates to methods for the diagnosis and evaluation of neoplastic disorders, particularly non-small cell lung cancer. Assays are described in which patient test samples are analyzed for the presence of one or more specific EML4-ALK fusion genes associated with neoplastic disorders.

US Patent:

20130344495, Dec 26, 2013

Filed:

Dec 29, 2011

Appl. No.:

13/997868

Inventors:

Heather R. Sanders - Winchester CA, US

International Classification:

C12N 15/10

US Classification:

435 612

Abstract:

The invention provides methods for isolating RNA from whole urine and urine fractions for the diagnosis of prostate cancer and/or benign prostate hyperplasia. An exemplary method for diagnosing prostate cancer in an individual, said method comprises: (a) determining the amount of RNA encoding one or more diagnostic genes in the soluble urine fraction of a urine sample obtained from said individual; (b) comparing the amount of said RNA to a reference value for said one or more diagnostic genes, wherein said reference value is derived from the amount of RNA encoding said one or more diagnostic genes in one or more individuals that do not have prostate cancer; and (c) diagnosing said individual as having prostate cancer when the amount of said RNA is greater than said reference value.

US Patent:

20200354712, Nov 12, 2020

Filed:

May 29, 2020

Appl. No.:

16/887079

Inventors:

- Secaucus NJ, US
Heather R. Sanders - Winchester CA, US

Assignee:

Quest Diagnostics Investments LLC - Secaucus NJ

International Classification:

C12N 15/10
C12Q 1/6806
C12Q 1/6886

Abstract:

The invention provides methods for isolating RNA from whole urine and urine fractions for the diagnosis of prostate cancer and/or benign prostate hyperplasia. An exemplary method for diagnosing prostate cancer in an individual, said method comprises: (a) determining the amount of RNA encoding one or more diagnostic genes in the soluble urine fraction of a urine sample obtained from said individual; (b) comparing the amount of said RNA to a reference value for said one or more diagnostic genes, wherein said reference value is derived from the amount of RNA encoding said one or more diagnostic genes in one or more individuals that do not have prostate cancer; and (c) diagnosing said individual as having prostate cancer when the amount of said RNA is greater than said reference value.

US Patent:

20190365779, Dec 5, 2019

Filed:

Aug 17, 2017

Appl. No.:

16/325856

Inventors:

- Secaucus NJ, US
Heather R. Sanders - Winchester CA, US

Assignee:

Quest Diagnostics Investments LLC - Secaucus NJ

International Classification:

A61K 31/567
A61K 31/03
A61K 31/48

Abstract:

The present technology is related to methods for detecting genetic alterations underlying intracranial neoplasms such as pituitary adenomas, meningiomas, and craniopharyngiomas. The methods disclosed herein are useful in determining whether a patient harboring an intracranial tumor will benefit from or is predicted to be responsive to treatment with an individual therapeutic agent or a specific combination of therapeutic agents. Kits for use in practicing the methods are also provided.